Arecor Therapeutics PLC (LSE:AREC) — Market Cap & Net Worth
Market Cap & Net Worth: Arecor Therapeutics PLC (AREC)
Arecor Therapeutics PLC (LSE:AREC) has a market capitalization of $401.97K (GBX3.30 Billion) as of September 24, 2026. Listed on the LSE stock exchange, this UK-based company holds position #31139 globally and #956 in its home market, demonstrating a 8.02% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Arecor Therapeutics PLC's stock price GBX87.50 by its total outstanding shares 37756601 (37.76 Million). Also see total assets of Arecor Therapeutics PLC for a full breakdown of the balance sheet.
Arecor Therapeutics PLC Market Cap History: 2021 to 2026
Arecor Therapeutics PLC's market capitalization history from 2021 to 2026. Data shows change from $1.84 Million to $401.97K (-17.44% CAGR). Also see Arecor Therapeutics PLC cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
Arecor Therapeutics PLC is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$1.02 Billion | 0.04% | #248 of 722 |
Weight: Arecor Therapeutics PLC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Arecor Therapeutics PLC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Arecor Therapeutics PLC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check AREC live share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.22x
Arecor Therapeutics PLC's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.56x
Arecor Therapeutics PLC's market cap is 0.56 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $1.84 Million | $1.16 Million | -$6.17 Million | 1.59x | N/A |
| 2022 | $1.10 Million | $2.40 Million | -$9.26 Million | 0.46x | N/A |
| 2023 | $838.38K | $4.57 Million | -$8.55 Million | 0.18x | N/A |
| 2024 | $337.65K | $5.05 Million | -$10.24 Million | 0.07x | N/A |
| 2025 | $369.81K | $1.71 Million | $664.00K | 0.22x | 0.56x |
Competitor Companies of AREC by Market Capitalization
Companies near Arecor Therapeutics PLC in the global market cap rankings as of September 24, 2026. Review tangible net worth ratio of Arecor Therapeutics PLC to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Arecor Therapeutics PLC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.53 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #334 globally with a market cap of $80.46 Billion USD.
- CSL Ltd (AU:CSL): Ranked #451 globally with a market cap of $62.04 Billion USD ( AU$87.68 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #510 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.53 Billion | $514.99 |
| #334 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $80.46 Billion | $803.90 |
| #451 | CSL Ltd | AU:CSL | $62.04 Billion | AU$180.72 |
| #510 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $182.56 |
Arecor Therapeutics PLC Historical Marketcap From 2021 to 2026
Between 2021 and today, Arecor Therapeutics PLC's market cap moved from $1.84 Million to $ 401.97K, with a yearly change of -17.44%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX401.97K | +8.70% |
| 2025 | GBX369.81K | +9.52% |
| 2024 | GBX337.65K | -59.73% |
| 2023 | GBX838.38K | -23.96% |
| 2022 | GBX1.10 Million | -40.00% |
| 2021 | GBX1.84 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 23rd, 2026 the market cap of Arecor Therapeutics PLC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $401.97K USD |
| MoneyControl | $401.97K USD |
| MarketWatch | $401.97K USD |
| marketcap.company | $401.97K USD |
| Reuters | $401.97K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Arecor Therapeutics PLC
Arecor Therapeutics plc, a clinical stage biotechnology company, develops therapeutics that address diabetes, obesity and other cardiometabolic diseases in the United Kingdom. The company's lead therapeutic product is the AT278, a disruptor insulin which is designed to transform Automated Insulin Delivery (AID) systems to improve patient care for people living with diabetes. It also develops a no… Read more